Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations1
Introduction
The inherited basis of certain breast cancers has been confirmed with the description of three dominant genes, namely BRCA1, BRCA2 and p53. All display a loss of heterozygosity consistent with the role of a tumor suppressor gene. In one study of young women with breast cancer (age less than 30 years), 13% were found to have BRCA1 mutations [9]. For Jewish women less than 40 years old diagnosed with breast cancer, 21% were found to have the specific BRCA1 mutation, 185delAG [9]. It is possible that less than 10% of all breast cancer cases are due to these genes; however, important aspects of breast carcinogenesis may be revealed in these syndromes [10]. With the potential advent of widespread genetic testing, further description of these clinical syndromes is needed.
Through genetic linkage analysis BRCA1 was localized to 17q21 [13]. The BRCA1 gene contains 22 exons distributed over more than 100 kb of genomic DNA and encodes for a protein of 1863 amino acids [20]. Recently, both BRCA1 and BRCA2 have been associated with the Rad51 protein, which is involved in the integrity of the genome 27, 29. Reduced expression has also been identified in transformation to a neoplastic state, which is consistent with its role as a tumor suppressor gene [34]. Many mutations have been described with the majority resulting in a truncated protein [30]. The precise frequency of the mutated gene is unknown; however, it has been estimated to be approximately one in 800 in the normal population [24]. BRCA1 and BRCA2 mutations are identified in approximately 12 and 3% of young women with breast cancer, respectively 9, 16.
BRCA2 has been identified on chromosome 13q12–13 and likely accounts for a large proportion of non-BRCA1 familial breast cancer 33, 37. BRCA2 has been implicated in male breast cancer and it displays the characteristic loss of heterozygosity (LOH) consistent with a tumor suppressor gene [35]. Additionally, LOH at 13q12–13 has been seen in a variety of different tumors from BRCA2 carriers suggesting a possible role in tumorigenesis [12].
Younger women with breast cancer have more aggressive lesions with an increased risk of relapse and death 14, 21. Tumor aggressiveness is manifest by an elevated S-phase fraction, abnormal p53 expression and higher histologic grade 1, 18, 19, 22. For BRCA1-related breast cancer, Eisinger et al. [8]noted that histopathologic grade appeared to segregate as a genetic trait, thus establishing a genotype–phenotype correlation.
On the other hand, familial breast cancer has been described to have a more favorable survival outcome than sporadic breast cancer 2, 25. In the study by Marcus et al. [18], BRCA1-related breast cancer patients had a higher proliferation rate, greater disease-free survival and similar overall survival compared with sporadic controls. Thus, an interesting dichotomy appears to exist for patients with BRCA1-related breast cancer where pathologic analysis yields a more aggressive grade while survival is improved or comparable to sporadic cases.
The objectives of this report are to analyze overall survival in patients with defined BRCA1 and BRCA2 mutations, review histologic findings and describe the response to radiation therapy.
Section snippets
Ascertainment of patients
This study used patients who had previously been used in linkage analysis to localize BRCA1 or BRCA2 20, 30, 33. We included all patients with breast cancer found within the state of Utah who were BRCA1 or BRCA2 mutation carriers. Patients were cross-referenced with the Utah Cancer Registry (UCR). The UCR has complete statewide cancer incidence data since 1966 and has over 148 000 cases. Thirty BRCA1 patients were identified from seven kindreds and 20 BRCA2 patients were identified from five
Clinical parameters
The median and range for the ages of onset were 49.5 and 21–77 years for BRCA1-related breast cancer and 42 and 23–83 years for BRCA2-related breast cancer, respectively (Table 1). For the UCR control group (n=18 278) the mean age at presentation was 60 years (P=0.0001 versus the combined BRCA1 and BRCA2 group). The majority of patients had stage I or II disease and 52% (29/56) had positive axillary lymph nodes. In our case population of BRCA1- and BRCA2-related breast cancer T sizes 1 (tumor
Discussion
Patients with hereditary breast cancer present frequently at an earlier age. Interestingly, our study patients more closely approximated population-based studies than previous reports 8, 18, 25; nonetheless, they presented on average more than a decade younger compared with a population-based control group. These study patients were identified because of strong family histories of breast and/or ovarian cancer suggesting a highly penetrant autosomal dominant gene and consequently do not
Acknowledgements
This study was supported in part by grants CA55914, Army DAMD 17-94-J4260 and CA96446 and contract NO1-CN05222.
References (37)
- Albain, K.S., Allred, D.C. and Clark, G.M. Interactions between very young age and prognostic factors for disease-free...
- Albano, W.A., Recabaren, J.A., Lynch, H.T., et al. Natural history of hereditary cancer of the breast and colon. Cancer...
- Bentzen, S.M. and Overgaard, M. Relationship between early and late normal-tissue injury after postmastectomy...
- Bignon, Y.J., Fonck, Y. and Chassagne, M.C. Histoprognostic grade in tumours from families with hereditary...
- Boice, J.D., Harvey, E.B., Blettner, M., Stovall, M. and Flannery, J.T. Cancer in the contralateral breast after...
- Carter, L.C., Allen, C. and Hensone, D.E. Relation of tumor size, lymph node status and survival in 24 740 breast...
- Contesso, G., Mouriesse, H., Friedman, S., Genin, J., Sarrazin, D. and Rouesse, J. The importance of histologic grading...
- Eisinger, F., Stoppa-Lyonnet, D., Longy, M., Kerangueven, F., Noguchi, T. and Bailly, C. Germ line mutation at BRCA1...
- Fitzgerald, M.G., MacDonald, D.J., Krainer, M., et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with...
- Ford, D. and Easton, D.F. The genetics of breast and ovarian cancer. Br. J. Cancer 72: 805–812,...
Cited by (106)
A systematic review exploring the role of modern radiation for the treatment of Hereditary or Familial Breast Cancer
2022, Radiotherapy and OncologyBRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review
2015, Clinical OncologyCitation Excerpt :In five studies the mean observation time was reported for one homogenous group of participants [22,31,33,36,39]. The remaining studies did not report this [24,27,29,42]. Two studies tested for BRCA1 mutation [23,28], one for BRCA2 [29], the remainder for both [19–22,24–27,30,32–43].
Rates of reconstruction failure in patients undergoing immediate reconstruction with tissue expanders and/or implants and postmastectomy radiation therapy
2015, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Ours is the first study to examine the influence of BRCA status on RF in women with TE/I reconstruction receiving PMRT. Four studies (33-36) reported no increased acute or late toxicity from radiation in BRCA carriers. However, the majority of these women had breast conserving surgery and radiation or mastectomy and radiation without reconstruction.
Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review
2015, BreastCitation Excerpt :A second question is whether the higher cell radiosensitivity shown in the laboratory for BRCA1/2 carriers does result in a significantly higher normal tissue and tumour response to radiation in the clinical setting. The literature review shows no apparent clinical translation of this higher radiosensitivity in terms of acute or late toxicities, as already anticipated in the late nineties by Gaffney et al. and Pierce et al.: in these studies radiation therapy was not associated with an increased complication rate or tumourigenesis in BRCA1/2 mutation carriers compared to patients with sporadic cancer [37,57]. Thus despite the concern that radiation could have a deleterious effect on breast tissue, the DNA damage response of cells with only one normal copy of either BRCA1 – BRCA2 is either functionally not impaired or not impaired enough to have a clinical relevance.
Radiation therapy in the locoregional treatment of triple-negative breast cancer
2015, The Lancet Oncology
- 1
This work was presented at the 21st meeting of the International Association for Breast Cancer Research, 3 July 1996, Paris, France.